Gibson Dunn Advises Arrowhead Pharmaceuticals on Signing of Asset Purchase Agreement Between Sanofi and Visirna Therapeutics
Dan Mulloy
Gibson Dunn represented Arrowhead Pharmaceuticals on the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned … The post Gibson Dunn Advises Arrowhead Pharmaceuticals on Signing of Asset Purchase Agreement Between Sanofi and Visirna Therapeutics appeared first on Gibson Dunn .